Searched for
CIPLA RESPIRATORY ASSETS
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...
These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
Cipla Q3 Results: Net profit plunges 57% YoY to Rs 676 croreCipla Q3 Results: Cipla reported a 57% YoY drop in net profit to Rs 676 crore, impacted by lower gRevlimid sales in North America. Despite ...
Cipla Q2 Results: Net profit grows 4% YoY to Rs 1,351 crore; revenue rises 8%Cipla Q2 Results: Cipla reported a 4% YoY growth in net profit to Rs 1,351 crore and an 8% rise in revenue to Rs 7,589 crore. The company s...
Cipla plans 4 major respiratory launches by 2026 after beating Q2 estimates with highest-ever quarterly revenue of Rs 7,500+ crCipla Ltd reported a record second-quarter revenue exceeding Rs 7,500 crore, driven by strong demand for its respiratory drugs and a growin...
Cipla targets $1 bn US revenue in FY27Cipla aims for $1 billion in US sales by FY27, offsetting Revlimid's patent expiry with new launches, particularly in respiratory generics ...
Cipla faces revenue and margin pressure ahead of Revlimid patent expiryCipla faces revenue and margin pressure due to the upcoming Revlimid patent expiry, leading to underperformance and analyst downgrades. Mar...
Cipla reports Rs 1049 crore net profit in Q3FY24, on strong US, India salesDrug maker Cipla reported a 33% year-on-year (YoY) jump in net profit to Rs 1049 crore in Q3FY24, led by strong US and India sales momentum.
Cipla Q3 Results: Profit jumps 32% YoY to Rs 1,056 crore, revenue rises 14%Cipla's Q3 revenue for the quarter grew 13.7% YoY to Rs 6,604 crore, compared to Rs 5,810 crore in the same quarter last year. However, the...
Cipla Q2 Results: Net profit jumps 45% YoY to Rs 1131 croreCipla's India business that contributes 42% to overall revenue grew 10% YoY to Rs 2817 crore in Q2FY24 with continued momentum across brand...
Cipla Q2 Results: Profit jumps 43% YoY to Rs 1,131 crore, revenue rises 15%The bottomline was higher than the Rs 1,006 crore which was expected by analysts in an ET Now poll. Cipla's consolidated margin came in at ...
Cipla Q3 Results: Profit rises 10% YoY to Rs 801 crore but misses estimates; stock hits 4-month lowThe dismal numbers from the drugmaker weighed on the stock, which extended the day’s losses and hit an over 4-month low of Rs 1,021. The sh...
Buy Cipla, target price Rs 1260: Axis SecuritiesCipla, incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 86522.68 Crore) operating in Pharmaceuticals sector.
Cipla sticks to 21-22% operating profit guidance for FY23, posts Rs 789 crore profit in Q2Cipla reported a multi-quarter high of $179 million in revenue and 25% YoY growth led by the successful launch of a generic version of the ...
Why Nithya Balasubramanian is gung-ho on Sun Pharma & Cipla“One gets different types of exposure with Sun Pharma and Cipla. For Sun, the capital allocation into US specialty is now bearing fruit. At...
Cipla skids 4% on Jan-Mar earnings missThe total revenue from operations was Rs 5,260.33 crore, up 14.19 per cent from Rs 4,606.45 crore the company reported in the year-ago quar...
Cipla Q4 Results: Profit falls 12.4% YoY to Rs 362 cr, misses estimatesThe total revenue from operations was Rs 5,260.33 crore, up 14.19 per cent from Rs 4,606.45 crore the company reported in the year-ago quar...